Cash & Equivalents
ResMed Cash & Equivalents increased by 17.2% to $1.66B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 78.0%, from $932.71M to $1.66B. Over 4 years (FY 2021 to FY 2025), Cash & Equivalents shows an upward trend with a 42.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $295.28M | $276.15M | $194.48M | $201.77M | $273.71M | $207.16M | $253.20M | $227.89M | $227.89M | $209.10M | $210.25M | $237.91M | $238.36M | $426.36M | $521.94M | $932.71M | $1.21B | $1.38B | $1.42B | $1.66B |
| QoQ Change | — | -6.5% | -29.6% | +3.8% | +35.7% | -24.3% | +22.2% | -10.0% | -0.0% | -8.2% | +0.5% | +13.2% | +0.2% | +78.9% | +22.4% | +78.7% | +29.7% | +14.4% | +2.4% | +17.2% |
| YoY Change | — | — | — | — | -7.3% | -25.0% | +30.2% | +12.9% | -16.7% | +0.9% | -17.0% | +4.4% | +4.6% | +103.9% | +148.3% | +292.0% | +407.4% | +224.6% | +171.5% | +78.0% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is ResMed's cash & equivalents?
- ResMed (RMD) reported cash & equivalents of $1.66B in Q1 2026.
- How has ResMed's cash & equivalents changed year-over-year?
- ResMed's cash & equivalents increased by 78.0% year-over-year, from $932.71M to $1.66B.
- What is the long-term trend for ResMed's cash & equivalents?
- Over 4 years (2021 to 2025), ResMed's cash & equivalents has grown at a 42.3% compound annual growth rate (CAGR), from $295.28M to $1.21B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.